EAM
KRTX

Eventide Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Eventide Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-190,000
Closed -$60.1M – 175
2023
Q4 		$60.1M Sell
190,000
-149,840
-44% -$29.1M 0.98% 39
2023
Q3 		$57.5M Sell
339,840
-128
-0% -$24.1K 1.03% 32
2023
Q2 		$73.7M Buy
339,968
+70
+0% +$15K 1.25% 27
2023
Q1 		$61.7M Sell
339,898
-179,802
-35% -$34.4M 1.13% 28
2022
Q4 		$102M Hold
519,700
– – 2.01% 12
2022
Q3 		$117M Sell
519,700
-99,700
-16% -$20.2M 2.3% 4
2022
Q2 		$78.4M Sell
619,400
-128,600
-17% -$14.8M 1.68% 19
2022
Q1 		$94.8M Hold
748,000
– – 1.49% 27
2021
Q4 		$98M Hold
748,000
– – 1.25% 30
2021
Q3 		$91.5M Hold
748,000
– – 1.21% 29
2021
Q2 		$85.3M Sell
748,000
-223,077
-23% -$26.1M 1.15% 34
2021
Q1 		$117M Buy
971,077
+70,000
+8% +$7.93M 1.73% 13
2020
Q4 		$91.5M Hold
901,077
– – 1.4% 19
2020
Q3 		$69.7M Hold
901,077
– – 1.36% 22
2020
Q2 		$100M Hold
901,077
– – 2.18% 9
2020
Q1 		$64.9M Buy
901,077
+686,234
+319% +$58.7M 2.1% 7
2019
Q4 		$16.2M Sell
214,843
-81,157
-27% -$3.55M 0.46% 67
2019
Q3 		$4.83M Sell
296,000
-840,234
-74% -$16.3M 0.16% 84
2019
Q2 		$22.1M Buy
+1,136,234
New +$22.7M 0.67% 56

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Eventide Asset Management's KRTX Position: Q1 2024 in Review

Eventide Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 190,000 shares — an estimated $60.1M sold.

Eventide Asset Management first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $117M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Eventide Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Eventide Asset Management sold 190,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $60.1M.
  • Eventide Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Eventide Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $117M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Eventide Asset Management's 13F filing for Q1 2024, filed 15 May 2024.